Zylox-Tonbridge Medical Technology Co., Ltd. Class H (2190) AI Stock Analysis

• Market Cap: HK$6.69B
• Dividend Yield: 0.54%
• Average Volume (3M): 503.99K
• Price to Earnings (P/E): 60.2
• Beta (1Y): 0.63
• Revenue Growth: 45.82%
• EPS Growth: N/A
• Country: HK
• Employees: 875
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Devices
• EPS (TTM): 0.11
• Shares Outstanding: 322,400,760
• 10 Day Avg. Volume: 329,712
• 30 Day Avg. Volume: 503,993
• PEG Ratio: 0.20
• Price to Book (P/B): 1.93
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -318.37
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$18.62
• Price Target Upside: -8.03% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 69 Neutral
• Price Target: ―

Zylox-Tonbridge Medical Technology benefits from strong revenue growth and a robust balance sheet, contributing positively to its stock score. However, the high P/E ratio and ongoing cash flow challenges weigh on its overall valuation. The stock exhibits strong technical momentum, although caution is advised due to potential overbought conditions.

Zylox-Tonbridge Medical Technology Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Zylox-Tonbridge Medical Technology Co., Ltd. Class H (2190) is a leading Chinese medical technology company specializing in the development, manufacturing, and sale of innovative medical devices. The company's core products focus on neuro-interventional and peripheral-vascular interventional medical devices, which are utilized for treating various vascular-related conditions. Zylox-Tonbridge is dedicated to advancing healthcare by providing high-quality and effective solutions that improve patient outcomes.

How the Company Makes Money

Zylox-Tonbridge Medical Technology Co., Ltd. generates revenue primarily through the sale of its medical devices, particularly in the neuro-interventional and peripheral-vascular interventional sectors. The company benefits from a strong distribution network and partnerships with healthcare providers, hospitals, and clinics, which facilitate the widespread adoption and use of its products. Additionally, Zylox-Tonbridge invests in research and development to continually enhance its product offerings, thereby maintaining a competitive edge and driving sales growth. The company's revenue streams are bolstered by its focus on innovation and strategic collaborations that expand its market reach both domestically and internationally.

Zylox-Tonbridge Medical Technology Co., Ltd. Class H Financial Statement Overview

Summary

Zylox-Tonbridge Medical Technology shows impressive revenue growth and improved profitability with a strong balance sheet. However, cash flow challenges persist, indicating a need for more stable cash generation from operations.

Income Statement

Zylox-Tonbridge Medical Technology shows significant revenue growth, with revenue increasing from HKD 5 million in 2019 to HKD 782 million in 2024. The gross profit margin has been consistently high, reaching 71.5% in 2024. Profitability has improved, with the net profit margin turning positive at 12.8% in 2024, up from negative margins in previous years. However, there were periods of EBIT and EBITDA losses, indicating operational challenges before 2024.

Balance Sheet

The company maintains a strong equity position, with a high equity ratio of 89.8% in 2024, reflecting financial stability. The debt-to-equity ratio has remained low, minimizing financial risk. High cash reserves and negative net debt emphasize liquidity strength. However, consistent growth in total liabilities over the years warrants monitoring.

Cash Flow

Zylox-Tonbridge has faced challenges with cash flow generation, as evidenced by fluctuating and often negative free cash flows. Operating cash flow turned negative in 2024, impacting cash flow sustainability. The reliance on financing activities in earlier years highlights the need for improved cash flow from operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	782.48M	527.75M	334.09M	177.91M	27.63M
Gross Profit	559.89M	384.99M	252.67M	131.88M	16.29M
EBITDA	65.30M	-41.60M	-86.56M	-199.94M	-90.16M
Net Income	100.26M	-78.73M	-120.41M	-186.05M	-99.48M
Balance Sheet
Total Assets	3.45B	3.38B	3.25B	3.25B	503.97M
Cash, Cash Equivalents and Short-Term Investments	1.28B	1.51B	1.86B	2.93B	317.26M
Total Debt	90.91M	55.88M	14.00M	9.40M	34.22M
Total Liabilities	351.56M	328.32M	159.54M	103.61M	79.28M
Stockholders Equity	3.10B	3.05B	3.09B	3.14B	424.69M
Cash Flow
Free Cash Flow	-17.26M	-92.48M	-236.60M	-205.80M	-127.47M
Operating Cash Flow	174.08M	98.44M	-91.32M	-116.21M	-82.33M
Investing Cash Flow	-801.36M	-206.24M	-95.05M	-1.33B	-249.18M
Financing Cash Flow	-41.98M	-11.46M	-30.26M	2.81B	345.54M

Zylox-Tonbridge Medical Technology Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 20.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2190, the sentiment is Positive. The current price of 20.25 is above the 20-day moving average (MA) of 19.89, above the 50-day MA of 19.50, and above the 200-day MA of 14.42, indicating a bullish trend. The MACD of 0.22 indicates Positive momentum. The RSI at 55.17 is Neutral, neither overbought nor oversold. The STOCH value of 26.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2190.

Zylox-Tonbridge Medical Technology Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2172	72 Outperform	HK$7.35B	26.43	15.22%	1.75%	12.48%	71.75%
2190	69 Neutral	HK$6.69B	60.23	3.22%	0.54%	45.82%	―
1302	65 Neutral	HK$7.47B	32.11	6.49%	―	0.87%	-18.05%
1858	64 Neutral	HK$7.27B	38.77	4.39%	0.77%	-32.05%	-54.47%
1789	62 Neutral	HK$6.24B	20.92	10.92%	1.29%	20.19%	45.54%
Sector *	60 Neutral	HK$16.12B	5.55	-7.44%	3.87%	11.55%	-28.15%
9996	51 Neutral	€5.10B	―	-10.43%	―	36.76%	42.89%

Zylox-Tonbridge Medical Technology Co., Ltd. Class H Corporate Events

Zylox-Tonbridge Grants 250,000 Awards to Boost Long-term Growth

Zylox-Tonbridge Medical Technology Co., Ltd. has granted 250,000 awards under its Share Award Scheme to a service provider involved in consultancy services related to the company’s product development. This grant aims to recognize and motivate the service provider, aligning their interests with the company’s long-term growth objectives. The awards are subject to performance targets and a clawback mechanism, ensuring alignment with the company’s strategic goals.

The most recent analyst rating on (HK:2190) stock is a Buy with a HK$18.60 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.

Zylox-Tonbridge Medical Technology Co., Ltd. Holds Successful 2024 AGM

Zylox-Tonbridge Medical Technology Co., Ltd. successfully held its 2024 Annual General Meeting (AGM) on May 30, 2025, where all proposed resolutions were approved unanimously. The meeting was conducted in compliance with relevant laws and regulations, with a significant portion of the company’s shares represented in the voting process, indicating strong shareholder support and engagement.

The most recent analyst rating on (HK:2190) stock is a Buy with a HK$18.60 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.

Zylox-Tonbridge Updates Final Dividend Details for 2024

Zylox-Tonbridge Medical Technology Co., Ltd. has announced an update regarding its final dividend for the year ended December 31, 2024. The dividend is set at RMB 0.1 per share, with a payment in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.089909. The ex-dividend date is June 4, 2025, and the payment date is June 27, 2025. The company will withhold a 10% tax for non-resident enterprise shareholders and a 20% tax for domestic individual shareholders, reflecting its compliance with tax regulations.

The most recent analyst rating on (HK:2190) stock is a Buy with a HK$18.60 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.

Zylox-Tonbridge Gains Approval for Listing Rule Changes, Reflecting Market Growth

Zylox-Tonbridge Medical Technology Co., Ltd. announced that it has received approval from the Hong Kong Stock Exchange to dis-apply certain listing rules, resulting in the removal of the ‘B’ marker from its stock name. This change reflects the company’s compliance with market capitalization and revenue requirements, signifying its growth and stability in the market.

Zylox-Tonbridge Announces 2024 AGM with Key Resolutions

Zylox-Tonbridge Medical Technology Co., Ltd. has announced its 2024 Annual General Meeting (AGM) scheduled for May 30, 2025, in Hangzhou, China. The AGM will address several key resolutions, including the approval of the 2024 financial auditing report, profit distribution plan, and the re-appointment of PricewaterhouseCoopers as the external auditor for 2025. Additionally, the meeting will consider granting the Board general mandates to issue shares and repurchase H Shares, which could impact the company’s financial strategy and shareholder value.

Zylox-Tonbridge Announces Final Dividend for 2024

Zylox-Tonbridge Medical Technology Co., Ltd. has announced a final cash dividend of RMB 0.1 per share for the financial year ending December 31, 2024. This announcement reflects the company’s financial health and commitment to providing value to its shareholders, with the payment date set for June 27, 2025, following shareholder approval on May 30, 2025.

Zylox-Tonbridge Announces Continued H Share Repurchase Plan

Zylox-Tonbridge Medical Technology Co., Ltd. has announced its intention to continue its H share repurchase plan, adjusting the maximum repurchase amount to HKD650 million due to the rising price of its H shares. The company believes that this move will demonstrate confidence in its business outlook and create value for shareholders, while maintaining a solid financial position. The repurchase is subject to regulatory approval in China and will be conducted at the discretion of the Board, depending on market conditions.

Zylox-Tonbridge Proposes 2024 Final Dividend Distribution

Zylox-Tonbridge Medical Technology Co., Ltd. has announced a proposed final dividend for the year ending December 31, 2024, amounting to RMB0.1 per share, totaling approximately RMB32,472,500.10. This proposal is subject to approval at the company’s annual general meeting in May 2025, with dividends to be paid in Renminbi for domestic and certain H Shares, and in Hong Kong dollars for others, based on the exchange rate set by the People’s Bank of China. If approved, the dividend will be distributed by June 27, 2025, with specific eligibility requirements for shareholders.